COMP <GO>
RCKT vs FULC // FREE CASH FLOW YIELD
Rocket Pharmaceuticals Inc. (NASDAQ) VS. Fulcrum Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RCKT 1
— FULC 2
■ METRIC PARITY
LAST: $2.54 (-1.55%) • MKT CAP: $278.8M
fcf-yield
—
LAST: $3.77 (+0.53%) • MKT CAP: $288.0M
fcf-yield
-20.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCKT VS. FULC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RCKT | FULC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | -20.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | RCKT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 48.8 | -3.56 | FULC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $278.8M | $288.0M | -$9.1M | FULC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RCKT REV | FULC REV | RCKT GROSS % | FULC GROSS % | RCKT FCF | FULC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$190.5M | -$60.4M |
| FY 2024 | $0 | $0 | — | — | -$215.6M | -$2.5M |
| FY 2023 | $0 | $0 | — | — | -$194.9M | -$91.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCKT // BETA —
FULC // BETA —